Monopar Therapeutics (NASDAQ:MNPR) Shares Down 1.8%

Monopar Therapeutics Inc. (NASDAQ:MNPR) dropped 1.8% on Wednesday . The stock traded as low as $0.56 and last traded at $0.58. Approximately 115,652 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 2,316,788 shares. The stock had previously closed at $0.59.

Wall Street Analyst Weigh In

MNPR has been the subject of several research analyst reports. Jonestrading upgraded Monopar Therapeutics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Thursday, April 11th. HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Monopar Therapeutics in a report on Friday, May 10th.

Monopar Therapeutics Stock Down 19.6 %

The company has a market capitalization of $7.73 million, a P/E ratio of -0.85 and a beta of 1.18. The company has a 50-day moving average of $0.73 and a two-hundred day moving average of $0.68.

Monopar Therapeutics shares are set to reverse split before the market opens on Tuesday, August 13th. The 1-5 reverse split was announced on Friday, August 9th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, August 12th.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.07. As a group, equities analysts expect that Monopar Therapeutics Inc. will post -0.37 EPS for the current fiscal year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.